AsthmaRelvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonists.• patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.